Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2021 Mar 2;11:4948. doi: 10.1038/s41598-021-84504-2

Machine learning-based prediction model using clinico-pathologic factors for papillary thyroid carcinoma recurrence

Young Min Park 1,, Byung-Joo Lee 2,
PMCID: PMC7925610  PMID: 33654166

Abstract

This study analyzed the prognostic significance of clinico-pathologic factors, including the number of metastatic lymph nodes (LNs) and lymph node ratio (LNR), in patients with papillary thyroid carcinoma (PTC), and attempted to construct a disease recurrence prediction model using machine learning techniques. We retrospectively analyzed clinico-pathologic data from 1040 patients diagnosed with PTC between 2003 and 2009. We analyzed clinico-pathologic factors related to recurrence through logistic regression analysis. Among the factors that we included, only sex and tumor size were significantly correlated with disease recurrence. Parameters such as age, sex, tumor size, tumor multiplicity, ETE, ENE, pT, pN, ipsilateral central LN metastasis, contralateral central LNs metastasis, number of metastatic LNs, and LNR were input for construction of a machine learning prediction model. The performance of five machine learning models related to recurrence prediction was compared based on accuracy. The Decision Tree model showed the best accuracy at 95%, and the lightGBM and stacking model together showed 93% accuracy. Among those factors mentioned above, LNR and contralateral LN metastasis were used as important features in all machine learning prediction models. We confirmed that all machine learning prediction models showed an accuracy of 90% or more for predicting disease recurrence in PTC. LNR and contralateral LN metastasis were used as important features for constructing a robust machine learning prediction model. In the future, we have a plan to perform large-scale multicenter clinical studies to improve the performance of our prediction models and verify their clinical effectiveness.

Subject terms: Medical research, Oncology, Risk factors

Introduction

Over the past 20 years, the incidence of thyroid cancer has increased rapidly, and the most common histologic type of thyroid cancer is papillary thyroid carcinoma (PTC)1. PTC has an excellent prognosis and a better survival rate than other carcinomas;however, disease ultimately recurs in about 5–21% of PTC patients2,3. In PTC patients with recurrent disease, surgical treatment is generally required, and re-operation poses additional medical costs and significant morbidity, compared to the initial surgery. Therefore, preventing recurrence in PTC patients can reduce and deteriorations in quality of life related to reoperation.

According to previous reports, tumor size, extrathyroidal extension (ETE), age, lymph node (LN) metastasis, tumor multiplicity, and extranodal spread (ENE) are known risk factors for recurrence of PTC46. In PTC, LN metastasis occurs in 20–90% of patients, and the number of metastatic LNs and lymph node ratio (LNR), representing metastatic LN burden, are known to be important prognostic factors associated with recurrence of PTC713. Since various clinico-pathological factors and nodal factors (i.e., number of metastatic LNs and LNR) have been shown to be related to the recurrence of PTC, these factors should be considered in an integrated manner to establish a disease recurrence prediction model.

The 8th TNM staging system was revised by the American Joint Committee on Cancer (AJCC) to more accurately predict the disease-specific survival of PTC patients. However, it does not reflect the biological behavior of PTC and has limitations in predicting the risk of recurrence1416. In particular, the number and size of metastatic LNs are not reflected in the revised TNM staging system. Also, the N classification of the revised TNM stage system merely comprises three groups and does not consider other nodal factors1722. We presume that the more prognostic factors, such as number of metastatic LNs and LNR, that can be integrated into the TNM system, the more accurate the prediction model could be for predicting disease recurrence of PTC patients.

Machine learning technology is widely used in the medical field, especially in the fields of radiology, ophthalmology, and dermatology2328. However, studies on the construction of machine learning models that can be used to predict disease recurrence of PTC are extremely rare. Establishing a robust predictive model of PTC could help with selecting high-risk patients for intensified treatment tailored according to risk stratification and with suggesting candidates for active follow-up. This study analyzed the prognostic significance of various clinico-pathologic nodal factors, including the number of metastatic LNs and LNR, in patients with PTC patients and attempted to construct a disease recurrence prediction model based on these factors using machine learning techniques.

Materials and methods

This study was approved by the Institutional Review Board (IRB) of Pusan University. Informed consent was not obtained from any participants because the IRB waived the need for individual informed consent. This retrospective research was performed in accordance with the Declaration of Helsinki. Medical data of patients diagnosed and treated for PTC at Pusan National University Hospital from June 2003 to December 2009 were analyzed retrospectively. We included patients who were diagnosed with PTC and underwent total thyroidectomy and central neck dissection with/without lateral neck dissection. We excluded (1) cases with a distant metastasis at the time of diagnosis, (2) patients who received previous surgery or radiotherapy to the head and neck area, and (3) cases with insufficient clinical data that were lost to follow-up after surgery. Finally, 1040 patients were included in the study, including 147 males and 893 females. Their ages ranged from 13 to 79 years and the mean age was 48.5 years. Tumor stage was classified according to the 8th AJCC staging system.

To detect disease recurrence, all patients underwent physical examination, ultrasound, and thyroglobulin measurement every 6–12 months after surgery. If necessary, additional imaging studies such as computed tomography, whole body iodine scan, and positron emission tomography were performed. Recurrence was defined as a case in which a new lesion was detected that was not previously observed in the imaging studies and which was pathologically confirmed through fine needle aspiration cytology.

Tumor size, ETE, multiplicity, ENE, and TNM stage were analyzed. The surgical specimens from central neck dissection were divided into ipsilateral and contralateral areas according to the location of the tumor, and therein the number of metastatic LNs and the total number of harvested LNs were recorded. LNR was calculated by dividing the number of metastatic LNs by the total number of harvested LNs. The cut-off value of LNR was determined in consideration of optimized sensitivity and specificity for predicting disease recurrence using receiver operating characteristic curves (ROC). The optimal value of LNR was used to construct machine learning models for predicting disease recurrences.

Machine learning was performed based on the supervised learning method, and a variety of machine learning models was used including the decision tree, random forest, XGBoost, and LightGBM, and Stacking models. Learning was performed with the five models mentioned above, and accuracy was used to evaluate model performance. Scikit-learn version 12.3 was used for model building and learning. 80% of the data set was classified as the training set and was used for learning, and the remaining 20% was used as a test set. To account for selection bias, the five-fold-cross-validation technique was applied.

Patient clinical information, pathologic information, recurrence, and cause of recurrence were analyzed. The Chi-square or independent two-sample t-test were used to evaluate differences in variables between two independent groups. The multivariate Cox proportional hazards regression model was used to evaluate the effect of several variables on disease recurrence. p values < 0.05 were considered indicative of statistical significance. Statistical analyses were performed using python 3.8 version and SPSS version 25.0 for Windows (SPSS, Chicago, IL).

Results

A total of 1040 patients were included in this study, and all patients underwent total thyroidectomy and central neck dissection. In total, 180 patients (17.3%) underwent lateral neck dissection simultaneously due to lateral LN metastasis. The average tumor size was 12.4 mm (range 2–125). ETE findings were observed in 586 (56.3%) patients, and tumor multiplicity was observed in 178 (17.1%) patients. ENE findings were observed in 159 patients (15.3%). With respect to T classification, 508 patients were classified as T1, 46 patients were T2, 483 patients were T3, and three patients were T4. The average number of metastatic LNs in the central compartment was 1.73 (range 0–19), and the average number of LNs removed was 8.32 (range 0–36). The average LNR value was 0.20 (range 0–1). The mean follow-up period was 79.0 months (range 46–149), and the total number of recurrence events during the study period was 41. Other clinico-pathological information is summarized in Table 1.

Table 1.

Clinical information for all patients (n = 1040) enrolled in the study.

Variable No. of patients (%)
Mean age, y (range) 48.5 (13–79)
Sex
Male 147 (14.1)
Female 893 (85.9)
Extrathyroidal extension
Yes 586 (56.3)
No 454 (46.7)
Tumor multiplicity
Yes 178 (17.1)
No 862 (82.9)
Extranodal extension
Yes 159 (15.3)
No 881 (84.7)
pT classification
1 508 (48.8)
2 46 (4.4)
3 483 (46.4)
4 3 (0.2)
pN classification
N0 506 (48.7)
N1a 354 (34.0)
N1b 180 (17.3)

The cut-off value for the LNR was set to show the optimal sensitivity and specificity for recurrence prediction. Regarding the prediction of recurrence, LNR showed a statistically significant correlation (p value =  < 0.001), with an AUC value of 0.752, and an LNR value of 0.24 was set as the optimal cut-off value. There were 519 patients (49.9%) with an LNR-of 0; 179 (17.2%) with an LNR value greater than 0, but less than 0.24; and 342 (32.9%) with an LNR value of 0.24 or more. Recurrence-free survival was significantly lower in the patient group with LNR > 0.24, compared to the other two groups (Fig. 1A). A cut-off value for the number of metastatic LNs was devised to obtain optimal sensitivity and specificity for recurrence prediction. The number of metastatic LNs was statistically significantly correlated with recurrence (p value =  < 0.001), with an AUC value of 0.742. A value of 2 was set as the cut-off for the number of metastatic LNs. There were 519 patients (49.9%) with 0 metastatic LNs, 161 (15.5%) with one LN metastasis, and 360 (34.6 with two or more LN metastases. Recurrence-free survival was analyzed by dividing patients into these three groups and was significantly decreased lower in patients with two or more metastatic LNs (Fig. 1B).

Figure 1.

Figure 1

(A) The cut-off value for the lymph node ratio (LNR) was determined in consideration of the sensitivity and specificity optimized to predict disease recurrence using a receiver operating characteristic curve (ROC). Recurrence-free survival of the patient group with LNR > 0.24 was significantly decreased. (B) The cut-off value for the number of metastatic LNs was determined in consideration of the sensitivity and specificity optimized to predict disease recurrence using a ROC. The recurrence-free survival of the patient group with two or more metastatic LNs was significantly decreased. (The graph was made by statistical software SPSS version 25.0 for windows).

We analyzed the association between clinico-pathologic factors and recurrence through univariate analysis. Sex, tumor size, ETE, pT classification, pN classification, number of metastatic LNs, and LNR were significantly correlated with disease recurrence. Clinico-pathologic factors related to recurrence were also analyzed with logistic regression for multivariate analysis. Among the factors included in the analysis, only sex and tumor size showed significant correlations with disease recurrence (Table 2).

Table 2.

Logistic regression analysis for disease recurrence adjusted for clinico-pathologic factors.

Factor Hazard ratio 95% CI p value
Sex 2.393 1.128–5.077 0.023
Size 1.030 1.007–1.052 0.010
ETE 3.105 0.697–13.834 0.137
pT 1.547 0.810–2.954 0.186
pN 0.790 0.170–3.683 0.765
Number of metastatic CLNs 1.619 0.582–4.502 0.356
LNR 1.337 0.480–3.725 0.578

CI confidence interval, ETE extrathyroidal extension, LN lymph node, LNR lymph node ratio.

To build a machine learning prediction model, the algorithm was trained using parameters of age, sex, tumor size, tumor multiplicity, ETE, ENE, pT, pN, ipsilateral central LN metastasis, contralateral central LN metastasis, number of metastatic LNs, and LNR. Since disease recurred in only 41 of 1040 cases, the SMOTE technique was applied to adjust for the imbalance in learning data. The performance of five machine learning models for recurrence prediction was compared based on accuracy. The decision tree model showed the best accuracy at 95%, and the LightGBM and stacking models showed accuracies of 93%. Table 3 summarizes the performance of the five models. The tree structure of the decision tree model was visualized using graphic software, and feature importance was also visualized and analyzed (Fig. 2). In other machine learning models, feature importance was explored to determine the major factors that influence the prediction of recurrence in PTC patients. Although the feature importance results differed slightly between machine learning models, LNR and contralateral LN metastasis were consistently important features in all models (Table 4).

Table 3.

Performance results for the machine learning models.

Model Accuracy Precision Recall F1 score
Decision tree 0.95 0.66 0.18 0.28
Random forest 0.91 0.25 0.27 0.26
XGBoost 0.92 0.25 0.18 0.21
LightGBM 0.93 0.28 0.18 0.22
Stacking 0.93 0.33 0.18 0.23

Figure 2.

Figure 2

The structure of the decision tree model was visualized using graphic software. (The graph was made using by python version 3.8, scikit-learn version 12.3, and graphviz software, All these software are open-sourec program).

Table 4.

Top five features of importance among machine learning models.

Rank Decision tree Random forest XGBoost LightGBM
1st Contralateral CLN metastasis LNR Tumor size Age
2nd LNR Ipsilateral CLNs metastasis Age Tumor size
3rd Age Contralateral CLNs metastasis Ipsilateral CLNs metastasis Ipsilateral CLNs metastasis
4th Tumor size LNR LNR
5th Age Contralateral CLNs metastasis Contralateral CLNs metastasis

LN lymph node, LNR lymph node ratio.

Discussion

The revised 8th TNM staging system is suitable for assessing the risk of death in patients with PTC, but not for predicting the risk of recurrence. Age, aggressive histology, tumor size, and LNs metastasis are known risk factors associated with PTC recurrence29. The 2015 American Thyroid Association guidelines suggested the number and size of metastatic LNs and ENE as risk factors for recurrence30,31. Meanwhile, LNR, calculated by dividing the number of metastatic LNs by the total number of removed LNs, has been reported in previous studies as a risk factor for recurrence of PTC13,32,33. Lee et al.34 reported that the performance of recurrence prediction increased when LNR was incorporated into the existing 2015 ATA risk stratification. In our study, the sensitivity and specificity for predicting disease recurrence were optimized when an LNR value of 0.24 was set as a cut-off. The number of metastatic LNs also showed a statistically significant correlation with the prediction of disease recurrence when 2 or more LNs was set as the cut-off value. To construct a robust prediction model for disease recurrence in PTC, these all factors mentioned above should be considered and integrated into the model.

In univariate analysis of risk factors for PTC recurrence, sex, tumor size, ETE, pT, pN, number of metastatic LNs, and LNR were significantly correlated with recurrence. In multivariate analysis using logistic regression, only tumor size showed a significant correlation with disease recurrence. Because logistic regression was used to analyze prognostic factors based on a linear combination between variables, if the degree of correlation between variables was high, the analysis was limited with overfitted results. On the other hand, since machine learning models do not assume a linear combination of variables used, the effect of correlation between variables can be diminished. Therefore, we can put all those prognostic factors including nodal factors such as LNR and number of metastatic LNs into the model and constructed machine learning prediction model. When analyzing the feature importance of parameters used for machine learning model construction, we noted that contralateral LN metastasis and LNR were used at high frequencies for machine learning model construction in all machine learning models, along with other clinical factors, including tumor size and age.

Among the machine learning techniques used in this study, the decision tree model showed the highest accuracy, followed by the Ensemble models, including LightGBM and stacking techniques. All of the machine learning models showed accuracies of 90% or more. However, since the models were trained based on data from 1000 patients, more patient data would be required to increase the performance of our models and to apply them in clinical practice. Also, additional research is needed to address the following limitations: Since this was a retrospective study conducted at a single institution, the influence of selection bias cannot be excluded. In addition, considering the indolent features of PTC, a short follow-up period is less optimal for detecting recurrence in PTC patients. Nevertheless, this study is of value as the first study on machine learning models of predicting PTC disease recurrence based clinico-pathologic factors.

In this study, various machine learning models were constructed for predicting disease recurrence in PTC patients, and all of the models had a confirmed accuracy of 90% or more. In the future, large-scale clinical studies on many patients should be performed to improve the performance of our prediction models, and multicenter clinical studies will be needed to verify their clinical effectiveness.

Acknowledgements

This study was supported by a Research Grant from Gangnam Severance Hospital, Yonsei University College of Medicine.

Author contributions

Y.M.P designed the study and collected data. Y.M.P wrote the machine learning code and performed training of it. Y.M.P drafted the manuscript with B.Y.L.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Young Min Park, Email: autumnfe79@yuhs.ac.

Byung-Joo Lee, Email: voiceleebj@gmail.com.

References

  • 1.Altekruse S, Das A, Cho H, Petkov V, Yu M. Do US thyroid cancer incidence rates increase with socioeconomic status among people with health insurance? An observational study using SEER population-based data. BMJ Open. 2015;5(12):e009843. doi: 10.1136/bmjopen-2015-009843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015;4(1):52–62. doi: 10.3978/j.issn.2227-684X.2014.12.06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Liu FH, Kuo SF, Hsueh C, Chao TC, Lin JD. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J. Surg. Oncol. 2015;112(2):149–154. doi: 10.1002/jso.23967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lan X, Sun W, Zhang H, Dong W, Wang Z, Zhang T. A Meta-analysis of central lymph node metastasis for predicting lateral involvement in papillary thyroid carcinoma. Otolaryngol. Head Neck Surg. 2015;153(5):731–738. doi: 10.1177/0194599815601412. [DOI] [PubMed] [Google Scholar]
  • 5.Yan H, Zhou X, Jin H, Li X, Zheng M, Ming X, Wang R, Liu J. A study on central lymph node metastasis in 543 cN0 papillary thyroid carcinoma patients. Int. J. Endocrinol. 2016;2016:1878194. doi: 10.1155/2016/1878194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chéreau N, Buffet C, Trésallet C, Tissier F, Leenhardt L, Menegaux F. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management. Surgery. 2016;159(3):755–762. doi: 10.1016/j.surg.2015.08.033. [DOI] [PubMed] [Google Scholar]
  • 7.Park CH, Song CM, Ji YB, Pyo JY, Yi KJ, Song YS, Park YW, Tae K. Significance of the extracapsular spread of metastatic lymph nodes in papillary thyroid carcinoma. Clin. Exp. Otorhinolaryngol. 2015;8(3):289–294. doi: 10.3342/ceo.2015.8.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ji YB, Song CM, Sung ES, Jeong JH, Lee CB, Tae K. Postoperative hypoparathyroidism and the viability of the parathyroid glands during thyroidectomy. Clin. Exp. Otorhinolaryngol. 2017;10(3):265–271. doi: 10.21053/ceo.2016.00724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am. Surg. 2005;71(9):731–734. doi: 10.1177/000313480507100907. [DOI] [PubMed] [Google Scholar]
  • 10.Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070–1071. doi: 10.1016/j.surg.2008.08.034. [DOI] [PubMed] [Google Scholar]
  • 11.Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: Addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139–148. doi: 10.1016/S0039-6060(03)00384-2. [DOI] [PubMed] [Google Scholar]
  • 12.Park YM, Wang SG, Lee JC, Shin DH, Kim IJ, Son SM, Mun M, Lee BJ. Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence. Head Neck. 2016;38(Suppl 1):E1172–E1176. doi: 10.1002/hed.24186. [DOI] [PubMed] [Google Scholar]
  • 13.Vas Nunes JH, Clark JR, Gao K, Chua E, Campbell P, Niles N, Gargya A, Elliott MS. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma. Thyroid. 2013;23(7):811–816. doi: 10.1089/thy.2012.0460. [DOI] [PubMed] [Google Scholar]
  • 14.Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol. Metab. Clin. N. Am. 2014;43(2):401–421. doi: 10.1016/j.ecl.2014.02.010. [DOI] [PubMed] [Google Scholar]
  • 15.Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed? Cancer. 2017;123(3):372–381. doi: 10.1002/cncr.30360. [DOI] [PubMed] [Google Scholar]
  • 16.Kim TH, Kim YN, Kim HI, Park SY, Choe JH, Kim JH, Kim JS, Oh YL, Hahn SY, Shin JH, Kim K, Jeong JG, Kim SW, Chung JH. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. Oral Oncol. 2017;71:81–86. doi: 10.1016/j.oraloncology.2017.06.004. [DOI] [PubMed] [Google Scholar]
  • 17.Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20(2):147–152. doi: 10.1089/thy.2008.0243. [DOI] [PubMed] [Google Scholar]
  • 18.Lang BH, Chow SM, Lo CY, Law SC, Lam KY. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann. Surg. 2007;246(1):114–121. doi: 10.1097/01.sla.0000262785.46403.9b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2007;92(11):4085–4090. doi: 10.1210/jc.2007-1179. [DOI] [PubMed] [Google Scholar]
  • 20.Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–1501. doi: 10.1001/jama.2013.3190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM. American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal Surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144–1152. doi: 10.1089/thy.2012.0043. [DOI] [PubMed] [Google Scholar]
  • 22.Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi: 10.1089/thy.2015.0020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mazo C, Bernal J, Trujillo M, Alegre E. Transfer learning for classification of cardiovascular tissues in histological images. Comput. Methods Prog. Biomed. 2018;165:69–76. doi: 10.1016/j.cmpb.2018.08.006. [DOI] [PubMed] [Google Scholar]
  • 24.Karri SP, Chakraborty D, Chatterjee J. Transfer learning based classification of optical coherence tomography images with diabetic macular edema and dry age-related macular degeneration. Biomed. Opt. Express. 2017;8(2):579–592. doi: 10.1364/BOE.8.000579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, Venugopalan S, Widner K, Madams T, Cuadros J, Kim R, Raman R, Nelson PC, Mega JL, Webster DR. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316(22):2402–2410. doi: 10.1001/jama.2016.17216. [DOI] [PubMed] [Google Scholar]
  • 26.Kermany DS, Goldbaum M, Cai W, Valentim CCS, Liang H, Baxter SL, McKeown A, Yang G, Wu X, Yan F, Dong J, Prasadha MK, Pei J, Ting MYL, Zhu J, Li C, Hewett S, Dong J, Ziyar I, Shi A, Zhang R, Zheng L, Hou R, Shi W, Fu X, Duan Y, Huu VAN, Wen C, Zhang ED, Zhang CL, Li O, Wang X, Singer MA, Sun X, Xu J, Tafreshi A, Lewis MA, Xia H, Zhang K. Identifying medical diagnoses and treatable diseases by image-based deep learning. Cell. 2018;172(5):1122–1131. doi: 10.1016/j.cell.2018.02.010. [DOI] [PubMed] [Google Scholar]
  • 27.Hood DC, De Moraes CG. Efficacy of a deep learning system for detecting glaucomatous optic neuropathy based on color fundus photographs. Ophthalmology. 2018;125(8):1207–1208. doi: 10.1016/j.ophtha.2018.04.020. [DOI] [PubMed] [Google Scholar]
  • 28.Tschandl P, Codella N, Akay BN, Argenziano G, Braun RP, Cabo H, Gutman D, Halpern A, Helba B, Hofmann-Wellenhof R, Lallas A, Lapins J, Longo C, Malvehy J, Marchetti MA, Marghoob A, Menzies S, Oakley A, Paoli J, Puig S, Rinner C, Rosendahl C, Scope A, Sinz C, Soyer HP, Thomas L, Zalaudek I, Kittler H. Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic study. Lancet Oncol. 2019;20(7):938–947. doi: 10.1016/S1470-2045(19)30333-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ito Y, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck. World J. Surg. 2011;35(4):767–772. doi: 10.1007/s00268-010-0924-3. [DOI] [PubMed] [Google Scholar]
  • 30.Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): What changed and why? Thyroid. 2017;27(6):751–756. doi: 10.1089/thy.2017.0102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Shah JP. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann. Surg. Oncol. 2016;23(2):410–415. doi: 10.1245/s10434-015-4762-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann. Surg. Oncol. 2013;20(6):1906–1911. doi: 10.1245/s10434-012-2802-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann. Surg. Oncol. 2014;21(1):277–283. doi: 10.1245/s10434-013-3258-1. [DOI] [PubMed] [Google Scholar]
  • 34.Lee J, Lee SG, Kim K, Yim SH, Ryu H, Lee CR, Kang SW, Jeong JJ, Nam KH, Chung WY, Jo YS. Clinical value of lymph node ratio integration with the 8(th) edition of the UICC TNM classification and 2015 ATA risk stratification systems for recurrence prediction in papillary thyroid cancer. Sci. Rep. 2019;9(1):13361. doi: 10.1038/s41598-019-50069-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES